The SHARP trial investigated the efficacy (usefulness) of the oral multikinase inhibitor sorafenib (Nexavar) in the treatment of hepatocellular carcinoma.
Â
The primary authors were Llovet JM, Ricci S, and Mazzaferro V, et al and the study results were published in the New England Journal of Medicine in 2008.
This phase III trial enrolled 602 patients who were randomized to receive supportive care or sorafenib.
The patients receiving the drug had a statisically significant longer survival (10.7 months) than those who received supportive care only (7.9 months.)
Leave a Reply